Drug Trial Radar · NCT04250363
Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model
Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Feb 17, 2020
Primary completion
Aug 18, 2021
Study completion Aug 18, 2021
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study was to assess the chemoprophylactic activity and dose-exposure-response relationship of single oral dose of M5717 administered after direct intravenous inoculation (DVI) of Plasmodium falciparum sporozoite (PfSPZ) challenge in healthy participants.
Conditions
- Healthy
Interventions
PfSPZ ChallengeBiological
Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
PalceboDrug
Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
M5717 30 mgDrug
Participants received 30 mg single oral dose of M5717 capsule on Day 1.
M5717 60 mgDrug
Participants received 60 mg single oral dose of M5717 capsule on Day 1.
M5717 80 mgDrug
Participants received 80 mg single oral dose of M5717 capsule on Day 1.
M5717 100 mgDrug
Participants received 100 mg single oral dose of M5717 capsule on Day 1.
M5717 200 mgDrug
Participants received 200 mg single oral dose of M5717 capsule on Day 1.
PlaceboDrug
Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
M5717 60 mgDrug
Participants received 60 mg single oral dose of M5717 capsule on Day 5.
M5717 100 mgDrug
Participants received 100 mg single oral dose of M5717 capsule on Day 5.
M5717 200 mgDrug
Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Liver Stage: Number of Participants Over Time With Positive ParasitemiaTime frame: Early Liver Stage: From Day 1 up to Day 28
- Late Liver Stage: Number of Participants Over Time With Positive ParasitemiaTime frame: Late Liver Stage: From Day 5 up to Day 32
- Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)Time frame: Early Liver Stage: From Day 1 up to Day 28
- Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)Time frame: Late Liver Stage: From Day 5 up to Day 32
- Early Liver Stage: Number of Participants With Documented Blood Stage Parasite GrowthTime frame: Early Liver Stage: From Day 1 up to Day 28
- Late Liver Stage: Number of Participants With Documented Blood Stage Parasite GrowthTime frame: Late Liver Stage: From Day 5 up to Day 32
- Early Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical ScoreTime frame: Early Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26 and 28
- Late Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical ScoreTime frame: Late Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30 and 32
- Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression ModelTime frame: From Day 5 up to Day 32
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Leiden University Medical Center
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.